



## **TRACON Pharmaceuticals to Present at the 29<sup>th</sup> Annual Roth Conference**

**San Diego, CA – March 6, 2017** -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, announced today that Charles Theuer, M.D, Ph.D., President and CEO, will present at the 29<sup>th</sup> Annual Roth Conference at 8:30 am PDT on Monday, March 13, 2017, at the Ritz Carlton in Dana Point, CA.

To access a live webcast of the presentation, please visit the “Events and Presentation” section within the “Investors” section of the TRACON Pharmaceuticals website at [www.traconpharma.com](http://www.traconpharma.com). A replay of the webcast will be available on the website for 60 days following the event.

### **About TRACON**

TRACON develops targeted therapies for cancer, ophthalmic and fibrotic diseases. The Company’s clinical-stage pipeline includes: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers; DE-122, the ophthalmic formulation of TRC105 that is being developed in wet AMD through a collaboration with Santen Pharmaceutical Company Ltd.; and TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma. To learn more about TRACON and its product candidates, visit TRACON's website at [www.traconpharma.com](http://www.traconpharma.com).

#### Company Contact:

Casey Logan  
Chief Business Officer  
(858) 550-0780 ext. 236  
[clogan@traconpharma.com](mailto:clogan@traconpharma.com)

#### Investor Contact:

Andrew McDonald  
LifeSci Advisors LLC  
646-597-6987  
[Andrew@lifesciadvisors.com](mailto:Andrew@lifesciadvisors.com)